[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635434":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":117,"collaborators":119,"id":134,"slug":135,"hasResults":136,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":136,"sex":142,"minAge":143,"maxAge":7,"enrollmentInfo":144,"targetDuration":7,"studyType":147,"phases":7,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":63,"whyStopped":7,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},{"fullName":5,"class":6},"University of Aarhus","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Morten Hansen, Medical Doctor","CONTACT","+45 20187463","mothas@rm.dk",[15,33,47,61,75,89,103],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Aalborg University Hospital, Department of Rheumatology","NOT_YET_RECRUITING","Aalborg","9000","Denmark","DK",{"type":23,"coordinates":24},"Point",[25,26],9.9187,57.048,{"lat":26,"lon":25},[29],{"name":30,"role":11,"phone":31,"phoneExt":7,"email":32},"Salome Kristensen, MD, PhD","+45 97664015","sakr@rn.dk",{"facility":34,"status":17,"city":35,"state":7,"zip":36,"country":20,"countryCode":21,"cosmosGeoPoint":37,"geoPoint":41,"contacts":42},"Aarhus University Hospital, Department of Rheumatology","Aarhus","8200",{"type":23,"coordinates":38},[39,40],10.21076,56.15674,{"lat":40,"lon":39},[43],{"name":44,"role":11,"phone":45,"phoneExt":7,"email":46},"Ellen Margrethe Hauge, MD, PhD","+45 2478 6025","ellen.hauge@aarhus.rm.dk",{"facility":48,"status":17,"city":49,"state":7,"zip":50,"country":20,"countryCode":21,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Rigshospitalet Glostrup, Center for Rheumatology and Spine Diseases Rigshospitalet","Glostrup Municipality","2600",{"type":23,"coordinates":52},[53,54],12.40377,55.6666,{"lat":54,"lon":53},[57],{"name":58,"role":11,"phone":59,"phoneExt":7,"email":60},"Lene Terslev, MD, PhD, DMSc","+45 35454131","terslev@dadlnet.dk",{"facility":62,"status":63,"city":64,"state":7,"zip":65,"country":20,"countryCode":21,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Regional Hospital Horsens, Department of Medicine","RECRUITING","Horsens","8700",{"type":23,"coordinates":67},[68,69],9.85034,55.86066,{"lat":69,"lon":68},[72],{"name":73,"role":11,"phone":7,"phoneExt":7,"email":74},"Berit Dalsgaard Nielsen, MD, PhD","beritnel@rm.dk",{"facility":76,"status":17,"city":77,"state":7,"zip":78,"country":20,"countryCode":21,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Hospitalsenhed Midt, Medicinsk Diagnostisk Center","Silkeborg","8600",{"type":23,"coordinates":80},[81,82],9.54508,56.1697,{"lat":82,"lon":81},[85],{"name":86,"role":11,"phone":87,"phoneExt":7,"email":88},"Søren Geill Kjær, MD","+45 6171 7078","soekjaer@rm.dk",{"facility":90,"status":17,"city":91,"state":7,"zip":92,"country":20,"countryCode":21,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Svendborg Hospital, Department of Medicine","Svendborg","5700",{"type":23,"coordinates":94},[95,96],10.60677,55.05982,{"lat":96,"lon":95},[99],{"name":100,"role":11,"phone":101,"phoneExt":7,"email":102},"Bill Aplin Frederiksen, MD","+45 6320 2246","Bill.Aplin.Frederiksen@rsyd.dk",{"facility":104,"status":17,"city":105,"state":7,"zip":106,"country":20,"countryCode":21,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Vejle Hospital, Department of Medicine","Vejle","7100",{"type":23,"coordinates":108},[109,110],9.5357,55.70927,{"lat":110,"lon":109},[113],{"name":114,"role":11,"phone":115,"phoneExt":7,"email":116},"Stavros Chrysidis, MD, PhD","+45 79409635","Stavros.Chrysidis@rsyd.dk",{"type":118,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[120,122,124,126,128,130,132],{"name":121,"class":6},"Aarhus University Hospital",{"name":123,"class":6},"Aalborg University Hospital",{"name":125,"class":6},"Svendborg Hospital",{"name":127,"class":6},"Glostrup University Hospital, Copenhagen",{"name":129,"class":6},"Vejle Hospital",{"name":131,"class":6},"Horsens Hospital",{"name":133,"class":6},"Regionshospitalet Silkeborg","100635434","disease-activity-monitoring-in-patients-with-giant-cell-arteritis-study-100635434",false,"NCT07552636","Disease Activity Monitoring in Patients With Giant Cell Arteritis Study","Disease Activity Monitoring in Patients With Giant Cell Arteritis","DiAcMo","Inclusion Criteria:\n\n1. Clinical GCA diagnosis established\u002Fconfirmed by a rheumatologist and positive GCA imaging or biopsy at diagnosis \\\u003C 3 years.\n2. Clinical remission at the time of inclusion, defined as\n\n   * Having adhered for ≥ 8 weeks prior to inclusion to either (a) the planned tapering of glucocorticoid therapy, or (b) the planned glucocorticoid-sparing DMARD treatment (with or without glucocorticoids).\n   * Absence of, or no worsening of, symptoms attributed to GCA in ≥ 8 weeks.\n   * Normal CRP level (\\\u003C 10 mg\u002FL) within 7 days before inclusion.\n3. Current prednisolone dosage of ≥ 5 mg if glucocorticoid monotherapy.\n4. A continuous tapering of monotherapy or combination therapy is planned.\n5. Age \\> 50 years.\n6. Study participants must be able to speak and understand spoken and written Danish.\n\nExclusion Criteria:\n\n1. Intra-articular, intravenous or intramuscular glucocorticoid ≤ 7 weeks prior to inclusion.\n2. Study participants who are unable to complete online questionnaires cannot participate in the GCA-PRO component of the study.\n3. Presence of cognitive impairment, including clinically significant dementia, that may interfere with the ability to provide informed consent or comply with study procedures.","ALL","50 Years",{"count":145,"type":146},175,"ESTIMATED","OBSERVATIONAL","Giant Cell Arteritis (GCA) is a vasculitis of medium- and large-sized arteries in older adults that may lead to serious vascular complications, including permanent vision loss and aortic aneurysm formation. Glucocorticoids are effective, but relapse during tapering is common and poses a major clinical challenge, potentially contributing to prolonged glucocorticoid exposure. Symptoms are often nonspecific and conventional inflammatory markers lack sufficient reliability, particularly in patients treated with drugs targeting the interleukin-6 pathway. Thus, this project aims to evaluate different tools assisting disease activity monitoring and\u002For predict future relapses and higher treatment requirements. Up to 175 patients with GCA in remission will be enrolled to ensure that 144 participants complete 1 year of follow-up. Participants undergo vascular ultrasonography, including double-blinded assessment at suspected relapse, complete patient-reported outcome measures, and provide biobank blood samples.",[150],"Giant Cell Arteritis (GCA)",[152,153,154,155],"vascular ultrasonography","disease activity monitoring","giant cell arteritis","patient-reported outcome measures","2026-05-27",{"date":158,"type":159},"2026-05-29","ACTUAL",{"date":161,"type":159},"2026-05-06",{"date":163,"type":146},"2029-02",{"name":5,"class":6},7]